Traws Pharma Files 8-K: Agreements and Equity Sales

Ticker: TRAW · Form: 8-K · Filed: Apr 15, 2026

Sentiment: neutral

Topics: material-agreement, equity-sale, filing

TL;DR

Traws Pharma dropped an 8-K on 4/15/26 detailing new deals and stock sales.

AI Summary

Traws Pharma, Inc. filed an 8-K on April 15, 2026, reporting a material definitive agreement, unregistered sales of equity securities, and other events. The filing includes various exhibits such as the 8-K document itself, and several exhibits related to agreements and financial statements.

Why It Matters

This 8-K filing indicates significant corporate actions by Traws Pharma, including new agreements and the issuance of equity, which could impact its financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and regulatory risks.

Key Numbers

Key Players & Entities

FAQ

What type of material definitive agreement did Traws Pharma enter into?

The filing indicates Item 1.01: Entry into a Material Definitive Agreement, but the specific details of the agreement are not provided in the summary text.

What were the details of the unregistered sales of equity securities?

The filing mentions Item 3.02: Unregistered Sales of Equity Securities, but specific details regarding the number of shares, price, or purchasers are not in the provided text.

What are the key exhibits filed with this 8-K?

Key exhibits include the 8-K document itself (EX-4.1, EX-4.2, EX-4.3, EX-4.4), agreements (EX-10.1, EX-10.2), and other information (EX-99.1).

What is Traws Pharma's business address and contact number?

Traws Pharma's business address is 12 PENNS TRAIL NEWTOWN PA 18940, and their contact number is 267-759-3680.

What is the SIC code for Traws Pharma, Inc.?

The SIC code for Traws Pharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 15, 2026 regarding Traws Pharma, Inc. (TRAW).

View full filing on EDGAR

View on Read The Filing